Immunotherapy of immunosenesence; who, how and when?

Sheila Govind, Antonio Lapenna, Pierre Olivier Lang, Richard Aspinall

Research output: Contribution to journalReview article

10 Citations (Scopus)
7 Downloads (Pure)

Abstract

Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals, how they might best be treated and when.

Original languageEnglish
Pages (from-to)56-63
Number of pages8
JournalOpen Longevity Science
Volume6
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Social Welfare
Immunotherapy
Immunity
Vaccination
History
Economics
Demography
Infection
Population

Bibliographical note

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Keywords

  • Frailty
  • Healthy ageing
  • Immunosenescence
  • Rejuvenation
  • Reversion

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Immunotherapy of immunosenesence; who, how and when? / Govind, Sheila; Lapenna, Antonio; Lang, Pierre Olivier; Aspinall, Richard.

In: Open Longevity Science, Vol. 6, 2012, p. 56-63.

Research output: Contribution to journalReview article

Govind, Sheila ; Lapenna, Antonio ; Lang, Pierre Olivier ; Aspinall, Richard. / Immunotherapy of immunosenesence; who, how and when?. In: Open Longevity Science. 2012 ; Vol. 6. pp. 56-63.
@article{9371404c40374a69a7d645409a37197d,
title = "Immunotherapy of immunosenesence; who, how and when?",
abstract = "Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals, how they might best be treated and when.",
keywords = "Frailty, Healthy ageing, Immunosenescence, Rejuvenation, Reversion",
author = "Sheila Govind and Antonio Lapenna and Lang, {Pierre Olivier} and Richard Aspinall",
note = "This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",
year = "2012",
doi = "10.2174/1876326X01206010056",
language = "English",
volume = "6",
pages = "56--63",
journal = "Open Longevity Science",
issn = "1876-326X",
publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Immunotherapy of immunosenesence; who, how and when?

AU - Govind, Sheila

AU - Lapenna, Antonio

AU - Lang, Pierre Olivier

AU - Aspinall, Richard

N1 - This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

PY - 2012

Y1 - 2012

N2 - Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals, how they might best be treated and when.

AB - Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals, how they might best be treated and when.

KW - Frailty

KW - Healthy ageing

KW - Immunosenescence

KW - Rejuvenation

KW - Reversion

UR - http://www.scopus.com/inward/record.url?scp=84856858722&partnerID=8YFLogxK

U2 - 10.2174/1876326X01206010056

DO - 10.2174/1876326X01206010056

M3 - Review article

VL - 6

SP - 56

EP - 63

JO - Open Longevity Science

JF - Open Longevity Science

SN - 1876-326X

ER -